LON:DDDD 4D pharma (DDDD) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About 4D pharma Stock (LON:DDDD) Get 4D pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.21 million shsAverage Volume2.96 million shsMarket Capitalization£30.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview 4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom. Read More Receive DDDD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DDDD Stock News HeadlinesYieldMax® ETFs Announces Quarterly Distribution for the U.S. Stocks Target Double Distribution ETF (DDDD)September 30 at 6:55 AM | globenewswire.comYieldMax® ETFs Announces First Quarterly Distribution for the U.S. Stocks Target Double Distribution ETF (DDDD)July 1, 2026 | globenewswire.comHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.October 2 at 1:00 AM | Chaikin Analytics (Ad)You Already Own SCHD. This New ETF Pays Twice the Yield With One Simple SwapMarch 19, 2026 | 247wallst.com4D Molecular Therapeutics expands phase 3 trial enrollmentDecember 10, 2025 | msn.com4D Molecular Therapeutics Appoints New Chief Financial OfficerNovember 17, 2025 | msn.com4D Molecular Therapeutics Names Kristian Humer Chief Financial OfficerNovember 17, 2025 | marketwatch.comChardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy RecommendationNovember 12, 2025 | msn.comSee More Headlines DDDD Stock Analysis - Frequently Asked Questions How were 4D pharma's earnings last quarter? 4D pharma plc (LON:DDDD) announced its earnings results on Wednesday, September, 30th. The company reported ($14.06) earnings per share (EPS) for the quarter. How do I buy shares of 4D pharma? Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of 4D pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D pharma investors own include Omega Diagnostics Group (ODX), Tullow Oil (TLW), B&M European Value Retail (BME), BP (BP), Coats Group (COA), genedrive (GDR) and Greencore Group (GNC). Company Calendar Last Earnings9/30/2020Today10/02/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:DDDD CIKN/A Webwww.4dpharmaplc.com Phone+44-113-8950130FaxN/AEmployees106Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (15.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£31.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-89.48% Return on Assets-42.64% Debt Debt-to-Equity Ratio39.50 Current Ratio5.21 Quick Ratio4.72 Sales & Book Value Annual Sales£718 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.44 Book ValueGBX 18 per share Price / BookN/AMiscellaneous Outstanding Shares180,340,000Free FloatN/AMarket Cap£30.05 million OptionableNot Optionable Beta2.63 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (LON:DDDD) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DDDD Stock Alerts